<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01127828</url>
  </required_header>
  <id_info>
    <org_study_id>U-05-008</org_study_id>
    <nct_id>NCT01127828</nct_id>
  </id_info>
  <brief_title>Effects of Cultura Yoghurt in Irritable Bowel Syndrome (IBS) Patients on Intestinal and Immunological Changes</brief_title>
  <official_title>Effects of Cultura Yoghurt on Symptoms Intestinal Flora and Immunological Changes in Patients With Irritable Bowel Syndrome(IBS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Good Food Practice, Sweden</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Good Food Practice, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of cultura probiotic yoghurt on number of responders to treatment
      during 8 weeks of treatment in comparison to placebo. To determine the effect of cultura
      yoghurt on change in total score of (IBS) irritable bowel syndrome severity index during 8
      weeks of treatment in comparison to placebo in IBS out patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent research has shown taht probiotic may give positive effect on symptoms among patients
      with (IBS) Irritable Bowel Syndrome. The mechanism behind the positive effect are not known
      but a positive effect on different cytokines are a possible mechanism. Also effect on the
      large intestine bacterial mass could be of importance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relief of IBS symptoms</measure>
    <time_frame>6 weeks intervention and 6 weeks follow up</time_frame>
    <description>The primary endpoint of this study was the proportions of patients reporting adequate relief of their IBS symptoms at least 50 % of the weeks during the treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects on gastrointestinal and extraintestinal symptoms</measure>
    <time_frame>September 2005 to May 2006</time_frame>
    <description>effects of the investigational products on GI and extraintestinal symptoms assessed with the weekly IBS SSI questionnaire and the scores from the daily questions of the GI symptom questionnaire as weel as the effect on psychological symptoms and quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Relief of Irritable Bowel Syndrome Symptoms</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Probiotic yoghurt (Cultura)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cultura yoghurt containing: L bulgaricus, S thermophilus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Yoghurt with no probiotic</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Arla Yoghurt with no probiotic</intervention_name>
    <description>two servings of 200 ml of investigational products per day</description>
    <arm_group_label>Yoghurt with no probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Probiotic yoghurt (Cultura)</intervention_name>
    <description>200 ml per day</description>
    <arm_group_label>Probiotic yoghurt (Cultura)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Signed consent to participate age 18-70 years IBS according to Rome II criteria

        Exclusion Criteria:

          1. Participation in a clinical study one month prior to screening visit and throughout
             the study.

          2. Abnormal results of the screening laboratory tests clinically relevant for study
             participation, as judged by the investigator.

          3. Other gastrointestinal disease(s) that explains the patient's symptoms, as judged by
             the investigator.

          4. Other severe disease(s) such as malignancy, severe coronary disease, kidney disease or
             neurological disease, as judged by the investigator.

          5. Symptoms indicating other severe disease(s) such as gastrointestinal bleeding, loss of
             weight or fever, as judged by the investigator.

          6. Severe psychiatric disease as judged by the investigator.

          7. Previous history of drug or alcohol abuse six months prior to screening.

          8. Intolerance or allergy against milk products or gluten.

          9. Use of other probiotic products (according to sponsor's list) 2 weeks prior to the
             study and throughout the study.

         10. Consumption of antibiotic drugs 1 month prior to screening and throughout the study.

         11. Consumption of cortisone, NSAID or other anti-inflammatory drugs on a regular basis 2
             weeks prior to screening and throughout the study.

         12. Pregnant or lactating or wish to become pregnant during the period of the study.

         13. Lack of suitability for participation in the study for any reason as judged by the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magnus Simrén, Ass Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicine, Sahlgrenska University Hospital, S 413 45 Gothenburg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Magnus Simren, Ass prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska hospital, Gothenburg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Magnus Simrén, Ass proff</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicine, Sahlgrenska University Hospital, S 413 45 Gothenburg, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>May 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2010</study_first_posted>
  <last_update_submitted>May 21, 2010</last_update_submitted>
  <last_update_submitted_qc>May 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Magnus Simrén</name_title>
    <organization>Sahlgrenska University Hospital</organization>
  </responsible_party>
  <keyword>IBS (Irritable Bowel Syndrome)</keyword>
  <keyword>Probiotic yoghurt</keyword>
  <keyword>Symptom severity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

